Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth (Q35215799)

7 August 2017

1 reference

title

Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth (English)

1 reference

7 August 2017

1 reference

Cecilia Sgadari

1

0 references

Paolo Monini

object named as

Paolo Monini

series ordinal

2

0 references

Barbara Ensoli

object named as

Barbara Ensoli

series ordinal

4

0 references

author name string

Giovanni Barillari

series ordinal

3

1 reference

7 August 2017

publication date

1 September 2003

1 reference

Lancet Oncology Commission

7 August 2017

published in

1 reference

7 August 2017

volume

4

1 reference

7 August 2017

issue

9

1 reference

7 August 2017

page(s)

537-547

1 reference

HIV-1 protease inhibitors

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Long-term exposure to lifelong therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Select HIV protease inhibitors alter bone and fat metabolism ex vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Mechanism of indinavir-induced hyperbilirubinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Not just research tools--proteasome inhibitors offer therapeutic promise

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

The human 26S proteasome is a target of antiretroviral agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Aids-related malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Improved outcome of cervical neoplasia in HIV-infected women in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Reactivation and role of HHV-8 in Kaposi's sarcoma initiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Kaposi's sarcoma associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Identification of human herpesvirus 8-specific cytotoxic T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active an

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Early reduction of immune activation in lymphoid tissue following highly active HIV therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Clearance of HHV-8 from peripheral blood mononuclear cells with a protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Distribution of the natural killer-related receptor for HLA-C during highly active antiretroviral therapy for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Mechanism of paclitaxel activity in Kaposi's sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Tumor targeting with a selective gelatinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

New functions for the matrix metalloproteinases in cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Inflammatory cells and cancer: think different!

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Involvement of proteasomes in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901192-6

7 January 2021

10.1016/S1470-2045(03)01192-6

Identifiers

DOI

1 reference

7 August 2017

1 reference